{"id":"osalmid","rwe":[],"tags":[{"label":"osalmid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"oxaphenamid","offLabel":[],"synonyms":["osalmid","oksafenamide","osalmide","oxaphenamid","oxaphenamide","salmidochol"],"timeline":[],"approvals":[],"brandName":"Oxaphenamid","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"osalmid","explanation":"Think of it like a key fitting into a lock. Oxaphenamid is like the key, and the target is like the lock. When the key fits into the lock, it can change the way the lock works, which in this case, could potentially treat a disease or condition.","oneSentence":"Oxaphenamid works by binding to a specific target, although its exact mechanism of action is not yet fully understood.","technicalDetail":"Oxaphenamid is a small molecule that modulates the activity of its target through a specific binding interaction, although the precise details of this interaction are not yet fully elucidated."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2000","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=OSALMID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OSALMID","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:11:11.528239","biosimilars":[],"competitors":[],"genericName":"osalmid","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03670173","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Assessments of Osalmid in Multiple Myeloma","status":"UNKNOWN","sponsor":"Shanghai 10th People's Hospital","startDate":"2018-10-01","conditions":["Multiple Myeloma"],"enrollment":20,"completionDate":"2021-05-18"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"89741L759Z","CHEBI":"CHEBI:31938","INN_ID":"1768","UMLSCUI":"C2698660","ChEMBL_ID":"CHEMBL389507","KEGG_DRUG":"D01579","DRUGBANK_ID":"DB16273","PUBCHEM_CID":"4602","MESH_SUPPLEMENTAL_RECORD_UI":"C005414"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":16,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxaphenamid, also known as osalmid, is a small molecule drug in the osalmid class. Its exact target is unknown, but it is being developed for potential therapeutic applications. The commercial status of osalmid is currently unclear, and it is not yet FDA-approved for any indications. Further research is needed to determine its efficacy and safety profile. As a result, key safety considerations and approved indications are not yet established.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}